[Transmission of AIDS virus by transfusion and blood products. Risks and preventive strategies].
This article reviews some of the epidemiologic aspects of transmission of LAV through transfusion of blood and blood products in the light of data available until late December 1985 in France, Europe and the United States. As of December 1985, blood transfusion has been considered the etiologic factor in 2.58% of the 15,172 cases of AIDS reported in the USA and in 5.6% of 1,573 cases of AIDS registered in Europe. Whole blood, cellular blood components and plasma derivatives except Albumin and immunoglobulins have been incriminated in 1.75 to 2.22 of the above percentages. Hemophiliacs under long term therapy by factor VIII and factor IX concentrates (0.83 to 3.36 of the above percentages) represent a highly exposed group when one considers the small proportion of these individuals in the general population (1/10,000 inhabitants). Three preventive measures have been officially implemented in the French transfusion network: self refrainment and deferral of prospective donors belonging to risk factor groups, systematic screening of donated blood for the presence of anti-LAV antibodies and elimination of seropositive units, heat treatment of coagulation factor concentrates to achieve viral inactivation. Information and medical follow up of LAV-contaminated donors thus identified and of their partners represent an important issue among the current public health problems.